The other part that is glossed over is even included on the snippets they posted up is where CAR-T therapies are being used more and more, earlier in the treatment process, so you'll see those numbers increase. Which means more failing off the treatment... Down the track, (a big if all things going well), Azercel will be positioned to sit with or in front of the current CAR-T treatments as it offers several advantages that have been covered in the presentations. Interesting times and glad to see something come out of the research.
IMU Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)